Nicox S.A. (NICXF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Nicox S.A. (NICXF) Healthcare & Pipeline Overview

Nicox S.A. is a French ophthalmology company focused on developing and commercializing innovative treatments for ocular diseases, including lead candidates NCX 470 (Phase 3 for glaucoma) and NCX 4251 (Phase 2b for blepharitis). With a specialized pipeline and existing commercial products, the company addresses significant unmet needs in global eye care.

What Is the Investment Thesis for NICXF?

Nicox S.A. presents an investment profile centered on its specialized ophthalmology pipeline and existing commercial products. A primary value driver is NCX 470, currently in a Phase 3 clinical trial for open-angle glaucoma or ocular hypertension. Successful completion and regulatory approval of NCX 470 could significantly enhance the company's market position, tapping into a substantial global market for intraocular pressure reduction. The company also has NCX 4251 in Phase 2b for acute blepharitis, offering another potential growth avenue. The company's existing commercial products, VYZULTA and ZERVIATE, provide current revenue streams, although the company operates with a profit margin of -14.4%, indicating a focus on R&D investment. A gross margin of 39.0% suggests efficiency in product delivery once commercialized. With a market capitalization of $29.2M and a Beta of 0.53, Nicox exhibits characteristics typical of a smaller biotechnology company with lower volatility relative to the broader market. Key catalysts include clinical trial readouts for NCX 470 and NCX 4251, potential regulatory submissions, and expansion of commercial product sales. Risks include clinical trial failures, regulatory hurdles, and intense competition in the ophthalmology sector.

Based on FMP financials and quantitative analysis

NICXF Key Highlights

Lead product candidate, NCX 470, is currently in a pivotal Phase 3 clinical trial for open-angle glaucoma or ocular hypertension.

• The company maintains a gross margin of 39.0%, reflecting efficiency in its product-related operations.
• Nicox S.A. is advancing NCX 4251, a proprietary fluticasone formulation, through a Phase 2b clinical trial for acute exacerbations of blepharitis.
• With a market capitalization of $29.2M, Nicox operates as a specialized biotechnology company focused on ophthalmology.
• The company's Beta of 0.53 suggests lower volatility compared to the broader market, characteristic of certain biotechnology segments.

Who Are NICXF's Competitors?

NICXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NICXF's Key Strengths?

Advanced clinical pipeline with NCX 470 in Phase 3 for glaucoma, a large market.

• Existing commercial products (VYZULTA, ZERVIATE) provide revenue and market presence.
• Specialized focus on ophthalmology, fostering deep expertise.
• Proprietary nitric oxide-donating technology for differentiated treatments.

What Are NICXF's Weaknesses?

Negative profit margin (-14.4%) indicates unprofitability.

• Small employee base (28 employees) may limit operational scale and R&D capacity.
• Reliance on successful clinical trial outcomes for future growth.
• OTC market listing may impact liquidity and investor perception.

What Could Drive NICXF Stock Higher?

Positive clinical trial readouts for NCX 470 (Phase 3 for glaucoma/ocular hypertension).

• Progression of NCX 4251 from Phase 2b to Phase 3 for acute exacerbations of blepharitis.
• Potential regulatory submissions and approvals for NCX 470 in key markets.
• Expansion of market penetration and sales growth for existing commercial products, VYZULTA and ZERVIATE.

What Are the Key Risks for NICXF?

Negative return on equity (-51.2%) — the business is not currently generating profit on shareholder capital.

• Clinical trial failures or unexpected adverse events for NCX 470 or NCX 4251, leading to delays or discontinuation.
• Significant competition in the ophthalmology market from larger, more established pharmaceutical companies.
• Regulatory hurdles or delays in obtaining marketing approvals for pipeline candidates.
• Negative profit margin (-14.4%) indicates current unprofitability, potentially requiring future capital raises and dilution.
• Challenges in securing favorable reimbursement and market access for new products post-approval.

What Are the Growth Opportunities for NICXF?

• Successful Commercialization of NCX 470: The lead product candidate, NCX 470, is in Phase 3 clinical trials for open-angle glaucoma and ocular hypertension. Successful completion of these trials, followed by regulatory approval, represents a significant growth opportunity. The global glaucoma market is projected to reach substantial valuations, driven by an aging population and increasing prevalence. As a novel nitric oxide-donating prostaglandin analog, NCX 470 could offer a differentiated treatment option, potentially capturing a meaningful share of this market by providing enhanced efficacy in intraocular pressure reduction, thereby driving future revenue growth for Nicox S.A.
• Advancement of NCX 4251 in Blepharitis Treatment: Nicox is developing NCX 4251, a proprietary fluticasone formulation, currently in a Phase 2b clinical trial for acute exacerbations of blepharitis. Blepharitis is a common ocular condition, and a successful development pathway for NCX 4251 could address a significant patient need for effective, targeted treatments. The market for blepharitis treatments, while perhaps smaller than glaucoma, still represents a multi-million dollar opportunity. Positive clinical data and subsequent progression to later-stage trials and eventual commercialization would broaden Nicox's product portfolio and revenue streams beyond glaucoma.
• Expansion of VYZULTA and ZERVIATE Market Penetration: Nicox currently offers VYZULTA for glaucoma/ocular hypertension and ZERVIATE for allergic conjunctivitis. While these products are already commercialized, there remains potential for increased market penetration through expanded geographic reach, new marketing initiatives, or strategic partnerships. Maximizing the sales performance of these existing assets can provide stable revenue streams, supporting ongoing R&D efforts and contributing to overall company growth. Continued adoption of these products in existing and new markets represents a tangible opportunity for near-to-mid-term financial improvement.
• Development of NCX 1728 and Future Pipeline Assets: The company's pipeline includes NCX 1728, an earlier-stage candidate, indicating a commitment to long-term innovation. While specific details on NCX 1728 are limited, the successful progression of this or other undisclosed early-stage assets could unlock future therapeutic areas or improved treatment modalities. A robust and continuously replenished pipeline is crucial for sustained growth in the biotechnology sector, ensuring future product offerings as current assets mature. This ongoing R&D effort is vital for maintaining competitive relevance and addressing evolving medical needs in ophthalmology.
• Strategic Partnerships and Licensing Opportunities: Given Nicox S.A.'s specialized focus and advanced pipeline, there is a potential for strategic partnerships, licensing agreements, or collaborations with larger pharmaceutical companies. Such alliances could provide additional funding for R&D, leverage broader commercialization networks, and accelerate market access for its product candidates. For a company of Nicox's size, securing favorable partnerships for global distribution or co-development could significantly de-risk its pipeline and provide substantial non-dilutive capital, enhancing its ability to compete and grow within the highly competitive ophthalmology market.

What Are NICXF's Competitive Advantages?

• Proprietary Nitric Oxide-Donating Technology: Unique expertise in developing nitric oxide-donating compounds for ophthalmic applications, offering a differentiated mechanism of action.
• Advanced Clinical Pipeline: Lead product candidate NCX 470 in Phase 3 and NCX 4251 in Phase 2b represent significant R&D investment and potential for market exclusivity upon approval.
• Approved Commercial Products: VYZULTA and ZERVIATE provide established market presence and revenue streams, validating the company's development capabilities.
• Specialized Focus: Dedicated solely to ophthalmology, allowing for deep expertise and targeted resource allocation in a specific therapeutic area.

What Does NICXF Do?

Nicox S.A., founded in 1996 and headquartered in Valbonne, France, operates as a specialized ophthalmology company with a mission to develop and commercialize innovative solutions aimed at maintaining vision and improving overall ocular health. Over its history, Nicox has evolved into a key player within the biotechnology sector, particularly focusing on eye care. The company's strategic approach involves both advancing its proprietary pipeline of drug candidates and commercializing approved products through partnerships. At the core of Nicox's development efforts is NCX 470, a novel nitric oxide-donating prostaglandin analog. This lead product candidate is currently in a pivotal Phase 3 clinical trial, targeting the reduction of intraocular pressure in patients diagnosed with open-angle glaucoma or ocular hypertension. The progression of NCX 470 through late-stage clinical development represents a significant focus for the company, given the substantial global burden of glaucoma. Beyond NCX 470, Nicox is also advancing NCX 4251, a proprietary formulation of fluticasone. This candidate is undergoing a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis, an inflammatory condition of the eyelid. The company's pipeline further includes NCX 1728, an earlier-stage asset, demonstrating a commitment to continuous innovation in ophthalmology. In addition to its robust development pipeline, Nicox has successfully brought two important products to market. VYZULTA (latanoprostene bunod ophthalmic solution) is designed to treat patients with open-angle glaucoma or ocular hypertension, leveraging its nitric oxide-donating mechanism to enhance efficacy. ZERVIATE (cetirizine ophthalmic solution) provides relief for ocular itching associated with allergic conjunctivitis. These commercialized products, along with its pipeline, position Nicox S.A. as a dedicated entity in the global ophthalmology market, addressing a range of eye conditions from chronic diseases to acute inflammatory states. The company's international operations underscore its ambition to deliver its treatments to a broad patient population.

What Products and Services Does NICXF Offer?

• Develops novel nitric oxide-donating compounds for ophthalmic conditions.
• Conducts Phase 3 clinical trials for NCX 470, targeting open-angle glaucoma and ocular hypertension.
• Advances NCX 4251, a proprietary fluticasone formulation, through Phase 2b for acute blepharitis.
• Commercializes VYZULTA (latanoprostene bunod ophthalmic solution) for glaucoma and ocular hypertension.
• Offers ZERVIATE (cetirizine ophthalmic solution) for ocular itching associated with allergic conjunctivitis.
• Engages in research and development of earlier-stage candidates like NCX 1728.
• Operates internationally, focusing on global ocular health solutions.

How Does NICXF Make Money?

• Research and Development: Invests in preclinical and clinical development of proprietary drug candidates.
• Licensing and Partnerships: Collaborates with pharmaceutical companies for the development and commercialization of its products, such as VYZULTA and ZERVIATE.
• Product Sales: Generates revenue from the sales of its approved ophthalmic solutions, VYZULTA and ZERVIATE, through its partners.
• Milestone Payments: Potentially receives milestone payments from partners upon achieving specific development or sales targets for licensed products.

What Industry Does NICXF Operate In?

Nicox S.A. operates within the global ophthalmology market, a segment of the broader healthcare and biotechnology industry characterized by significant unmet medical needs and continuous innovation. The company's focus on conditions like open-angle glaucoma, ocular hypertension, and blepharitis places it in therapeutic areas with substantial patient populations and market potential. The glaucoma market, for instance, is driven by an aging global demographic and the chronic nature of the disease, necessitating long-term treatment solutions. Similarly, blepharitis represents a common inflammatory condition requiring effective management. The competitive landscape in ophthalmology is robust, featuring both large pharmaceutical companies with diversified portfolios and specialized biotechnology firms. Nicox differentiates itself through its nitric oxide-donating technology, particularly with NCX 470, which aims to offer an improved mechanism for intraocular pressure reduction. The industry is marked by high R&D costs, lengthy clinical trial processes, and stringent regulatory requirements, making successful pipeline progression a critical factor for market positioning and growth. Nicox's strategy involves advancing its proprietary candidates while leveraging existing commercial products to secure its niche.

Who Are NICXF's Key Customers?

• Ophthalmologists and eye care professionals who prescribe the company's treatments.
• Patients suffering from open-angle glaucoma, ocular hypertension, blepharitis, and allergic conjunctivitis.
• Pharmaceutical partners who license and commercialize Nicox's approved products.
• Healthcare systems and payers that cover ophthalmic medications.

Wall Street analysts project Nicox S.A. revenue of about $3.0M for fiscal 2026, with EPS near $-0.07.

Nicox S.A. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 38.7% below estimates on average.

Nicox S.A.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.

Return on equity for Nicox S.A. stands at -51.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -23.3%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.2%, the inverse of the P/E and a quick read on earnings relative to price.

Nicox S.A. (NICXF) Valuation Context

Valued at $29.2M, NICXF is classified as a micro-cap stock. Relative to its peer group, NICXF's quantitative score of 55/100 is below the peer average of 76/100.

NICXF Revenue & Earnings Trend

In Q4 2025, NICXF generated $15.2M in top-line revenue, marking a sequential increase of 893.1%. The company recorded net income of $6.5M, with diluted EPS of $0.09. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.

Company Profile

Nicox S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Biot, FR. The company is led by CEO Gavin Spencer. NICXF has traded publicly since 2010.

NICXF Financials

NICXF Latest News

NICXF Analyst Consensus

NICXF MoonshotScore

Common Questions About NICXF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources